From: Dyslipidemia and cardiovascular disease risk among the MASHAD study population
 | Dyslipidemia | High LDL-C | High TC | High TG | Low HDL-C |
---|---|---|---|---|---|
Total population | |||||
 Total CVD | |||||
  Crude HR (95%CI) | 1.81 (1.15–2.87)* | 1.54 (1.19–2)** | 1.53 (1.18–1.98)** | 1.57 (1.21–2.03)** | 1.15 (0.87–1.52) |
  Multivariable HR (95%CI)* | 1.14 (0.68–1.89) | 1.16 (0.85–1.59) | 0.93 (0.68–1.26) | 1.13 (0.82–1.55) | 0.96 (0.69–1.33) |
 MI | |||||
  Crude HR (95%CI) | 2.12 (0.65–6.89) | 1.91 (1.03–3.55)* | 2 (1.07–3.73)* | 1.77 (0.95–3.30) | 1.08 (0.56–2.10) |
  Multivariable HR (95%CI)* | 1.90 (0.44–8.07) | 1.65 (0.83–3.30) | 1.46 (0.72–2.95) | 1.52 (0.75–3.09) | 0.80 (0.38–1.66) |
 SA | |||||
  Crude HR (95%CI) | 1.24 (0.62–2.49) | 1.52 (0.96–2.41) | 1.73 (1.10–2.73)* | 1.50 (0.95–2.37) | 1.23 (0.75–2.02) |
  Multivariable HR (95%CI)* | 0.90 (0.40–2.04) | 1.10 (0.61–1.97) | 1.02 (0.57–1.81) | 1.14 (0.63–2.05) | 1 (0.55–1.83) |
 UA | |||||
  Crude HR (95%CI) | 2.37 (1.15–4.85) | 1.43 (0.99–2.06) | 1.31 (0.92–1.89) | 1.58 (1.10–2.26) | 1.14 (0.77–1.68) |
  Multivariable HR (95%CI)* | 1.16 (0.55–2.43) | 1.03 (0.66–1.61) | 0.73 (0.47–1.14) | 1.01 (0.65–1.57) | 1.01 (0.63–1.62) |
Men | |||||
 Total CVD | |||||
  Crude HR (95%CI) | 1.43 (0.84–2.43) | 1.37 (0.93–2.03) | 1.36 (0.93–1.99) | 1.40 (0.96–2.05) | 1.01 (0.69–1.48) |
  Multivariable HR (95%CI)* | 0.95 (0.53–1.71) | 1.13 (0.71–1.81) | 1 (0.63–1.59) | 1.49 (0.94–2.35) | 0.90 (0.57–1.41) |
 MI | |||||
  Crude HR (95%CI) | 1.81 (0.54–6.03) | 1.86 (0.84–4.10) | 2.46 (1.12–5.43)* | 2.19 (0.99–4.82) | 1.02 (0.46–2.24) |
  Multivariable HR (95%CI)* | 1.95 (0.45–8.51) | 2.22 (0.94–5.26) | 2.71 (1.12–6.57)* | 2.35 (0.94–5.86) | 0.85 (0.36–2.04) |
 SA | |||||
  Crude HR (95%CI) | 0.86 (0.35–2.12) | 1 (0.44–2.28) | 1.14 (0.52–2.49) | 1.38 (0.64–2.94) | 1 (0.47–2.13) |
  Multivariable HR (95%CI)* | 0.58 (0.20–1.66) | 0.66 (0.22–2.03) | 0.62 (0.22–1.75) | 1.48 (0.56–3.91) | 0.83 (0.33–2.11) |
 UA | |||||
  Crude HR (95%CI) | 1.75 (080–3.87) | 1.38 (0.81–2.37) | 1.13 (0.66–1.93) | 1.16 (0.68–1.97) | 1.02 (0.61–1.72) |
  Multivariable HR (95%CI)* | 0.91 (0.40–2.11) | 1.01 (0.51–1.98) | 0.71 (0.36–1.39) | 1.18 (0.62–2.24) | 0.95 (0.50–1.81) |
Women | |||||
 Total CVD | |||||
  Crude HR (95%CI) | 3.71 (1.37–10.04)* | 1.74 (1.22–2.48)** | 1.75 (1.23–2.50)** | 1.70 (1.19–2.42)** | 1.52 (0.97–2.38) |
  Multivariable HR (95%CI)* | 1.95 (0.61–6.24) | 1.19 (0.77–1.82) | 0.83 (0.53–1.28) | 0.80 (0.51–1.25) | 1.12 (0.67–1.89) |
 MI | |||||
  Crude HR (95%CI) | _¤ | 2.23 (0.81–6.14) | 1.67 (0.60–4.60) | 1.08 (0.37–3.16) | 2.42 (0.55–10.74) |
  Multivariable HR (95%CI)* | _¤ | 1.31 (0.40–4.26) | 0.72 (0.21–2.41) | 0.67 (0.21–2.20) | 1.14 (0.24–5.49) |
 SA | |||||
  Crude HR (95%CI) | 1.84 (0.57–5.93) | 1.87 (1.06–.31)* | 2.16 (1.20–3.86)* | 1.61 (0.90–2.87) | 1.38 (0.68–2.77) |
  Multivariable HR (95%CI)* | 1.38 (0.32–5.92) | 1.30 (0.64–2.67) | 1.18 (0.57–2.46) | 0.92 (0.43–1.97) | 1.08 (0.47–2.45) |
 UA | |||||
  Crude HR (95%CI) | 7.55 (1.05–54.46)* | 1.51 (0.91–2.49) | 1.56 (0.95–2.57) | 2.03 (1.23–3.4)** | 1.52 (0.81–2.86) |
  Multivariable HR (95%CI)* | 2.75 (0.37–20.22) | 1.06 (0.57–1.94) | 0.66 (0.36–1.21) | 0.77 (0.41–1.43) | 1.20 (0.57–2.55) |